Jun 8, 2015 | News
T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details...
May 18, 2015 | News
T3D Therapeutics announced the addition of three new members to its Advisory Board complementing Alzheimer’s disease and CNS expertise with pharmaceutical licensing, clinical development and business acumen; Jason Kralic Ph.D., Stuart Hobbs, Pharm.D., and Wesley...
Mar 24, 2015 | News
NIA/NIH grant support for Phase 2a clinical testing of a new, potentially disease-modifying therapy tor Alzheimer’s disease. Read More
Jan 23, 2015 | News
T3D Therapeutics was one of only thirteen companies selected to participate in this year’s CED Life Science Conference Showcase, March 3-4, 2015. CED received over 70 applicants and the Selection Committee felt that T3D represented one of the best new companies in the...
Jun 4, 2014 | News
T3D Therapeutics announced it has been awarded a competitive $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center. The SRL Program funds research to advance development of commercially viable technologies/products. Through the SRL...